OncoMatch/Clinical Trials/NCT06118086
Study of REM-422 in Patients With Recurrent, Metastatic, or Unresectable Adenoid Cystic Carcinoma
Is NCT06118086 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies REM-422 for adenoid cystic carcinoma.
Treatment: REM-422 — The goal of this study is to determine the safety and antitumor effects of REM-422, a MYB mRNA degrader, in people with advanced Adenoid Cystic Carcinoma (ACC)
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Head and Neck Squamous Cell Carcinoma
Biomarker criteria
Required: MYB poison exon biomarker positive
Performance status
ECOG 0–1(Restricted strenuous activity)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of California San Francisco Helen Diller Comprehensive Cancer Center · San Francisco, California
- Dana Farber Cancer Research Institute · Boston, Massachusetts
- University of Michigan Rogel Cancer Center · Ann Arbor, Michigan
- Memorial Sloan Kettering Cancer Center · New York, New York
- Sarah Cannon Research Institute · Nashville, Tennessee
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06118086 currently recruiting?
Yes, this trial is currently recruiting patients.
Does this trial require MYB?
Yes, MYB poison exon biomarker positive is a required biomarker for enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages